Tag Archives: Research and Development

Patents Improve Public Health: Progressive Economy Reviews TRIPS at 20 Years

flags with blue sky

Progressive Economy released a research paper examining the effect of TRIPS (Trade-Related Aspects of Intellectual Property) on global health. Here are their findings quoted from their press release: “1. Since the TRIPS agreement went into effect on New Year’s Day 1995, research and development spending has risen significantly worldwide (relative to the size of GDP). For OECD members, the rise is from 2.1 percent to 2.4 percent of GDP, or in practice an additional $220 Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The Pivotal Role the Public Market Plays in Financing R&D

KennethMoch-Chimerix

Growing innovators are the heart of our industry. Biotech small businesses face a dual struggle – the daily challenge of running a growing company combined with the roadblocks intrinsic to groundbreaking scientific advancement. Innovative companies must overcome capital formation barriers in order to fund their next generation R&D.  The financing challenges that emerging biotechs face are unique, but we have the potential to save lives and treat patients in desperate need of hope. Today, I Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,

How to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor Conference

Fireside Chat

Like a number of companies, Eli Lilly is confronting a wave of patent expirations called the patent cliff. The company lost U.S. patent protection on the anti-psychotic Zyprexa in the fall of 2011 and they’re facing the losses of the antidepressant Cymbalta in December of 2013 and the osteoporosis drug Evista in 2014. The loss of protection endangers the company’s ability to profit from the drugs and they could face a $25 billion loss in Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Data Exclusivity Protects Innovators and Assures Investors

medical_research_thumb

Biotechnology companies must have some certainty that they can protect their investment in the development of new breakthrough therapies for a substantial period of time. This protection helps companies secure much-needed venture capital funding, which is the lifeblood of the industry. A failure to include substantial data exclusivity would undermine incentives to invest in biomedical innovation and thus would slow progress in the development of breakthrough therapies to improve the health and lives of patients Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Research: Working Together Toward Cures

Jim Greenwood

Modern biomedical innovation and the discovery of new cures and therapies for devastating diseases require robust collaboration and coordination among industry, research institutions and physicians. By bringing together the brightest minds in medical research, our nation’s research enterprise has successfully brought hundreds of new drugs, biologics, and vaccines to market in recent years and developed a wealth of clinical prescribing information. Ongoing research is advancing the fight against some of humanity’s worst scourges, such as Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , ,